Phase I clinical trial - Gynécologie - Ovaires

TG4050.01
Gynécologie - Ovaires
Ouvert depuis le: 09.19.2021
Site: Paris
Public cible
Adulte
A phase I trial evaluating a mutanome-directed immunotherapy in patients with high grade serous carcinoma (HGSC) of the ovary, fallopian tube or peritoneum who experience an asymptomatic relapse
Description de l'essai

This is a multicenter, open-label, single arm phase I study evaluating TG4050, an individualized active immunotherapy which refers to a mutanome-directed immunotherapy based on a Modified Virus Ankara (MVA) vaccine specifically designed to target tumor-specific antigens identified in each ovarian, fallopian or peritoneal HGSC patient with an asymptomatic relapse.